|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500104323 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-16 09:04:47 |
|
注册时间: Date of Registration: |
2025-06-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于脂代谢失衡精准营养干预晚期肿瘤患者生存期及生活质量的真实世界研究 |
|
Public title: |
Precise Nutritional Intervention Based on Lipid Metabolic Imbalance for Prolonging Survival and Improving Quality of Life in Advanced Cancer Patients:A Real World Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于脂代谢失衡精准营养干预晚期肿瘤患者生存期及生活质量的真实世界研究 |
|
Scientific title: |
Precise Nutritional Intervention Based on Lipid Metabolic Imbalance for Prolonging Survival and Improving Quality of Life in Advanced Cancer Patients:A Real World Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘向荣 |
研究负责人: |
刘英华 |
|
Applicant: |
Liu xiangrong |
Study leader: |
Liu yinghua |
|
申请注册联系人电话: Applicant telephone: |
+86 187 1636 3447 |
研究负责人电话:
Study leader's |
+86 10 6693 7785 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1305120549@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
liuyinghua77@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区复兴路28号 |
研究负责人通讯地址: |
北京市海淀区复兴路28号 |
|
Applicant address: |
No. 28, Fuxing Road, Haidian District, Beijing, China |
Study leader's address: |
No. 28, Fuxing Road, Haidian District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
解放军总医院第一医学中心 |
||
|
Applicant's institution: |
the first medical center of PLA General Hospital |
||
|
研究负责人所在单位: |
解放军总医院第一医学中心 |
||
|
Affiliation of the Leader: |
the first medical center of PLA General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
S2024-509-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
PLA General Hospital Medical Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-17 00:00:00 | ||
|
伦理委员会联系人: |
曹江 |
||
|
Contact Name of the ethic committee: |
Cao jiang |
||
|
伦理委员会联系地址: |
北京市海淀区复兴路28号 |
||
|
Contact Address of the ethic committee: |
No. 28, Fuxing Road, Haidian District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6693 7166 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
解放军总医院第一医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
the first medical center of PLA General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区复兴路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 28, Fuxing Road, Haidian District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
研究者自发 |
||||||||||||||||||||||
|
Source(s) of funding: |
Research initiated by the researcher |
||||||||||||||||||||||
|
研究疾病: |
非小细胞肺癌 |
||||||||||||||||||||||
|
Target disease: |
Non-small cell lung cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
1. 精准营养干预对晚期非小细胞肺癌患者营养状况及生活质量的影响; 2. 调查我国晚期非小细胞肺癌患者血液中不同中长链脂肪酸比例的分布; 3. 探索晚期非小细胞肺癌与脂肪代谢的关联。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.The Impact of Precision Nutritional Intervention on Nutritional Status and Quality of Life in Patients with Advanced Non-Small Cell Lung Cancer; 2.Investigation of the Distribution of Different Medium- and Long-Chain Fatty Acids in the Blood of Patients with Advanced Non-Small Cell Lung Cancer in China; 3.Exploration of the Association Between Advanced Non-Small Cell Lung Cancer and Lipid Metabolism |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、年龄18岁至80岁(含); 2、经病理明确的晚期NSCLC患者; 3、过去3个月内未接受营养支持治疗或额外营养补充剂; 4、受试者自愿参与研究并签署知情同意书; 5、可以理解问卷的内容,能够独自或在调查者的帮助下完成问卷的填写。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Aged 18 to 80 years (inclusive); 2. Patients with pathologically confirmed advanced NSCLC; 3. Have not received nutritional support treatment or additional nutritional supplements in the past 3 months; 4. The subject voluntarily participates in the study and signs the informed consent form; 5. Able to understand the content of the questionnaire and complete its filling independently or with the assistance of the investigator. |
||||||||||||||||||||||
|
排除标准: |
1. 处于重症监护状态; 2. 受试者填写问卷中途放弃,停止继续填写问卷; 3. 过去3个月内曾额外服用营养素的患者; 4. 研究者认为因其他原因不适合参与本研究的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. In intensive care status; 2. The subject gives up in the middle of filling out the questionnaire and stops filling in the questionnaire. 3. Patients who have taken additional nutrients in the past 3 months; 4. Patients who, in the opinion of the investigator, are not suitable to participate in this study for other reasons. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-09-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-06-16 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
利用随机数表,将入组患者随机分入对照组和干预组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Using a random number table, the enrolled patients were randomly assigned to the control group and the intervention group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究数据采集和管理使用病例记录表(Case Record Form, CRF) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
In this study, data collection and management were conducted using a Case Record Form (CRF). |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |